Lundbeck's alcohol dependence drug approved in Europe
This article was originally published in Scrip
Lundbeck's alcohol dependence treatment Selincro (nalmefene) has been approved by the European Commission. Anders Gersel Pedersen, head of R&D at Lundbeck, told Scrip that the real discussions about reimbursement of Selincro across Europe start now. "The feedback we have had so far is that there is a high level of interest. There is a clear recognition in many countries that this is a serious problem, and that this is an interesting approach to tackle it. They are positive about [Selincro] conceptually."
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.